Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 27;13:5062. doi: 10.1038/s41467-022-32477-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a, b Sustained p21 expression in vivo (DM-22; T1DM, STZ-model, (a); T2DM, db/db-model, (b) despite reducing glucose levels (DM + SGLT2i, (a); db/db+SGLT2i, (b) as compared to mice with persistently elevated glucose levels (DM-22, (a); db/db, (b) or normoglycemic controls (C, a; db/m, b). Exemplary immunoblots (a, b). GAPDH: loading control (bottom, a, b) and dot plots summarizing results (top, a, b). c Immunohistochemical images of sustained p21 expression in kidneys of T1DM (STZ-model, top) and T2DM (db/db model, bottom) diabetic mice despite reducing glucose levels (DM + SGLT2i) as compared to mice with persistenly elevated blood glucose levels (DM-22); C: normoglycemic controls. p21 is detected by HRP-DAB reaction, brown; hematoxylin nuclear counter stain, blue. Scale bars represent 20 µm. d Exemplary p21immunoblot (bottom; loading control: β-actin) and dot plot summarizing results (top) in mouse primary tubular cells (PTC), mouse mesangial cells (MES), mouse glomerular endothelial cells (GEC), or mouse podocytes (Pod) maintained under normo- (5 mM; C) or high glucose (25 mM; HG) conditions. e Sustained p21 expression in vitro (Human kidney cells, HEK293) despite reducing glucose levels. HEK-293 cells were maintained under normal glucose (5 mM, C), high glucose (48 h of 25 mM, HG), or high glucose followed by normal glucose (25 and 5 mM, each for 24 h, HG/NG). Exemplary immunoblots (bottom, GAPDH: loading control) and dot plots summarizing results (top). f Sustained p21 expression in vivo (STZ-model) despite reducing glucose levels using insulin (DM + INS) as compared to mice with persistently elevated glucose levels (DM-22) and normoglycemic controls (C). Exemplary immunoblots (bottom, GAPDH: loading control) and dot plots summarizing results (top). g Exemplary histological images of SA-β-gal stain (senescence associated β-galactosidase, blue; eosin counterstain) in T1DM (STZ-model, top and bottom) and T2DM (db/db model, middle) despite reducing glucose levels (DM + intervention; SGLT2i, top and middle or insulin, INS, bottom) as compared to mice with persistently elevated glucose levels (DM-22) or normoglycemic controls (C). Scale bars represent 20 µm. Dot plots reflecting mean ± SEM of 6 mice per group or 3 independent experiments; one-way ANOVA with Sidak’s multiple comparison test (a,b,e,f); t-test comparing C versus HG for each cell line (d) Gels/blots were processed in parallel; source data are provided as a Source Data file-Fig-2.